Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CAT | P04040 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18662417 | 1.00 | SIGMAR1 (0.42) | SIGMAR1CATTP53HPGDSMN1; SMN2 | |
| SCHEMBL17286495 | 0.86 | SMN1; SMN2 (0.44) | SIGMAR1HPGDSMN1; SMN2POLBKMT2A | |
| SCHEMBL18662389 | 0.86 | SMN1; SMN2 (0.44) | SIGMAR1HPGDSMN1; SMN2POLBKMT2A | |
| SCHEMBL18662446 | 0.84 | CAT (0.46) | CAT | |
| SCHEMBL18662445 | 0.84 | CAT (0.46) | CAT | |
| SCHEMBL23130145 | 0.83 | CAT (0.46) | CATKMT2AMEN1 | |
| SCHEMBL17347805 | 0.83 | CAT (0.46) | CATKMT2AMEN1 | |
| SCHEMBL15868268 | 0.82 | SIGMAR1 (0.40) | SIGMAR1TP53HPGDSMN1; SMN2POLB | |
| SCHEMBL18662396 | 0.82 | CAT (0.45) | CAT | |
| SCHEMBL18662395 | 0.82 | CAT (0.45) | CAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145936-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3145936-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9963467-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963467-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015179308-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | SIGMAR1 2622/4885CAT 128/4885TP53 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.